SCHEMBL3981479

SCHEMBL3981479

CCOC(=O)c1occc1-c1ccco1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
ALOX15 P16050 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
PKM P14618 1/20 0.52
POLB P06746 3/20 0.48
ADORA2B P29275 2/20 0.48
CACNA1D Q01668 1/20 0.47
KDM4E B2RXH2 5/20 0.45
MAPT P10636 4/20 0.45
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TSHR P16473 4/20 0.43
GAA P10253 1/20 0.43
ADORA3 P0DMS8 2/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982536 0.80 TSHR (0.47) ALDH1A1KMT2AMEN1HSD17B10ALOX15
SCHEMBL14255689 0.79 TSHR (0.59) ALDH1A1KMT2AMEN1HSD17B10TDP1
SCHEMBL3983011 0.78 CA1 (0.50) ALDH1A1KMT2AMEN1HSD17B10ALOX15
SCHEMBL3977130 0.77 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1HSD17B10ALOX15
SCHEMBL26559455 0.76 PRKCZ (0.52) ALDH1A1KMT2AMEN1L3MBTL1PKM
SCHEMBL3975204 0.76 CA12 (0.51) ALDH1A1KMT2AMEN1KDM4EMAPT
SCHEMBL3976773 0.75 ALDH1A1 (0.55) ALDH1A1KMT2AHSD17B10TDP1PKM
SCHEMBL1257007 0.75 MAPT (0.50) ALDH1A1KMT2AMEN1HSD17B10TDP1
SCHEMBL3982938 0.75 PTPN1 (0.46) ALDH1A1KMT2AMEN1HSD17B10TDP1
SCHEMBL106734 0.75 PRKCZ (0.53) ALDH1A1KMT2AMEN1HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543022-C 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound DAINIPPON PHARMACEUTICAL CO (JP) 2009-09-23 CN disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
CN-1628111-A 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 2005-06-15 CN disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 ALDH1A1 1389/4885KMT2A 3459/4885MEN1 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.